- Report
- February 2024
- 250 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- January 2024
- 175 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- June 2022
- 215 Pages
United States
From €2592EUR$2,699USD£2,232GBP
- Report
- June 2021
- 195 Pages
United States
From €2401EUR$2,500USD£2,067GBP
- Report
- October 2019
- 310 Pages
Global
From €3314EUR$3,450USD£2,853GBP
- Report
- June 2019
- 220 Pages
Global
From €2103EUR$2,190USD£1,811GBP
- Report
- January 2019
- 35 Pages
Global
From €960EUR$1,000USD£827GBP
Boostrix is a vaccine used to protect against diphtheria, tetanus, and pertussis (whooping cough). It is a combination of three antigens, which are proteins that stimulate the body's immune system to produce antibodies. Boostrix is typically administered as a single dose to adolescents aged 11-18 years old, and as a booster dose to adults aged 19-64 years old. It is also recommended for pregnant women in their third trimester.
Boostrix is part of a larger market of vaccines, which are used to prevent and control the spread of infectious diseases. Vaccines work by introducing a weakened or killed form of a virus or bacteria into the body, which stimulates the body's immune system to produce antibodies that protect against future infection.
The Boostrix market is highly competitive, with many companies offering similar products. Some of the major players in the market include GlaxoSmithKline, Sanofi Pasteur, Merck & Co., Pfizer, and Novartis. Show Less Read more